ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided EPS guidance of 7.370-7.640 for the period, compared to the consensus EPS estimate of 6.970. The company issued revenue guidance of $854.0 million-$873.0 million, compared to the consensus revenue estimate of $869.3 million. ANI Pharmaceuticals also updated its FY 2026 guidance to EPS.

Wall Street Analyst Weigh In

A number of analysts have recently commented on ANIP shares. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a report on Thursday, October 9th. JPMorgan Chase & Co. lifted their price target on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, September 24th. Guggenheim boosted their price objective on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Finally, Barclays initiated coverage on shares of ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 target price for the company. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.14.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $76.28 on Monday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of 46.80 and a beta of 0.51. ANI Pharmaceuticals has a one year low of $52.74 and a one year high of $99.50. The company’s 50-day moving average is $82.81 and its 200 day moving average is $83.29.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.30. The firm had revenue of $227.81 million for the quarter, compared to the consensus estimate of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The business’s revenue was up 53.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Sell-side analysts expect that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, Director Renee P. Tannenbaum sold 1,800 shares of ANI Pharmaceuticals stock in a transaction on Friday, December 5th. The stock was sold at an average price of $81.15, for a total value of $146,070.00. Following the completion of the sale, the director owned 25,157 shares of the company’s stock, valued at approximately $2,041,490.55. This trade represents a 6.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Meredith Cook sold 400 shares of the business’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $82.32, for a total value of $32,928.00. Following the completion of the transaction, the vice president owned 74,874 shares of the company’s stock, valued at $6,163,627.68. This represents a 0.53% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 27,601 shares of company stock worth $2,410,898. Insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ANIP. Advisors Asset Management Inc. bought a new position in shares of ANI Pharmaceuticals during the 1st quarter valued at $28,000. State of Wyoming purchased a new stake in ANI Pharmaceuticals during the second quarter valued at $50,000. Tower Research Capital LLC TRC increased its position in ANI Pharmaceuticals by 542.0% during the second quarter. Tower Research Capital LLC TRC now owns 1,727 shares of the specialty pharmaceutical company’s stock valued at $113,000 after acquiring an additional 1,458 shares during the last quarter. Vestcor Inc bought a new position in ANI Pharmaceuticals in the third quarter valued at about $213,000. Finally, CreativeOne Wealth LLC purchased a new position in ANI Pharmaceuticals in the third quarter worth about $221,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.